Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map ...
Recursion Pharmaceuticals Inc. RXRX) on Wednesday reported a loss of $162.3 million in its third quarter. The Salt Lake City-based company said it had a loss of 36 cents per share.
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is slated to report third-quarter 2025 results on Nov. 5, before the opening bell.
5d
‘Scream 7’ Trailer Haunted by Melissa Barrera’s Firing as Fans Call for Boycott: ‘Looks Terrible!’
Social media users took the "Scream" trailer to task in the wake of Barrera's removal following pro-Palestinian posts ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback